two men in suits shaking hands atop building

Our Partners

Atomo's numerous partners utilise our unique, innovative technology to bring a range of high-quality rapid diagnostic tests to global markets.

We work with a number of highly reputable partners in the diagnostic testing space. As a result of these partnerships, Atomo's technology is available in over 30 countries worldwide.

grey world map with red dots showing countries of location

NG Biotech

NG Biotech is a French innovative biotech company focusing on the development and manufacture of novel in vitro diagnostic tools for therapy monitoring at the point of care (Onsite).

Utilising Atomo's Pascal platform, NG's Precision+ pregnancy test offers results in 5 minutes through professional use channels. The blood-based test detects earlier and at a higher rate of accuracy than urine tests.

The NG Precision+ is available for purchase throughout Europe.

Teardrop with letters NG inside and words NG Biotech Laboratoires underneath


Headquartered in the United States, with three global centres in Pittsburgh, Pennsylvania, U.S., Shanghai, China, and Hyderabad, India, Viatris operates approximately 40 manufacturing facilities that produce complex dosage forms, injectables, oral solid doses and active pharmaceutical ingredients.

Utilising Atomo's Galileo platform, Viatris' Mylan HIV Self Test is sold through lower-middle income markets across the world, creating additional avenues for HIV testing in markets where significantly more barriers to clinical testing exist.

purple blue and yellow swirl around chequered globe with word Viatris to the right

Lumos Diagnostics

Lumos Diagnostics specialises in rapid, cost-effective and complete point-of-care (POC) diagnostic test solutions to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customised assay development and manufacturing services for POC tests and proprietary digital reader platforms. Lumos also directly develops, manufactures and commercialises proprietary, Lumos-branded POC tests that target infectious and inflammatory diseases.

Utilising Atomo's Pascal platform, Lumos' FebriDx platform is sold in Europe and under review with the US FDA. The test is authorised to identify and differentiate viral from bacterial acute respiratory infection. With 99% accuracy, this test has reduced antibiotic prescriptions by 80%, leading to better efficiencies and lower costs.

4 coloured circles with words Lumos Diagnostics underneath

Develop Future Tests With Us

Atomo’s unique technology presents an opportunity to improve existing products on the market with superior usability. Our integrated platforms can help users easily perform the tests on their own and improve performance, speed and reliability in a professional clinical setting.

We welcome dialogue with forward-thinking diagnostic partners who would like to explore co-developing tests for infectious diseases, allergy sensitivities, women’s health, men’s health, sexual health, heart health and other applications.

Man and woman sitting at desk looking at diagnostic test design on computer screen
Smiling woman leaning on the back of a smiling man in an outdoor setting with trees in the background

Re-imagining diagnostics